AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
In this article, we discuss 12 best dividend stocks that are undervalued and have just raised their payouts. You can skip our detailed analysis of dividend and value stocks and their previous performance, and go directly to read 5 Undervalued Stocks That Just Raised Their Dividends. Dividend stocks didn’t perform well in 2023. However, this […]